Nemes Laszlo Johnson & Johnson ( NYSE: JNJ ) and Legend Biotech ( NASDAQ: LEGN ) said that after a single infusion, the CART-T therapy Carvykti (ciltacabtagene autoleucel) led to durable responses in multiple myeloma patients who didn't achieve complete response after frontline autologous stem cell transplant. At median follow-up of 22 months, patients on Carvykti achieved a 94% overall response rate with all 16 patients achieving a complete response in a phase 2 study. Eighteen-month progression-free survival and overall survival rates were both 94%.
Legend Chief Medical Officer Mythili Koneru noted the companies are conducting a phase 3 study to see if Carvykti can be used as a frontline treatment. Carvykti is currently approved as a multiple myeloma treatment for those who have failed at least one prior therapy. More on Johnson & Johnson, Legend Biotech Johnson & Johnson: Market Will Regret The Overreaction Legend Biotech a new buy at Deutsche Bank on Carvykti sales Johnson & Johnson: Vital Signs Decent, A Compelling Value Case Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances J&J says Rybrevant combo bests AstraZeneca's Tagrisso in type of lung cancer.
